Source: Eur Respir J 2016; 48: 1517-1519



Rating:

Share or cite this content

Citations should be made in the following way:
Marianne Riou, Andrei Seferian, Laurent Savale, Marie-Camille Chaumais, Christophe Guignabert, Matthieu Canuet, Pascal Magro, Delphine Rea, Olivier Sitbon, Xavier Jaïs, Marc Humbert and David Montani. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J 2016; 48: 1517-1519

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 What is the incidence of pleural effusions in acute pulmonary emboli? Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Comparison of the immunologic profile between pleural effusion and cavitary parenchymal disease in young patients with pulmonary tuberculosis Source: Annual Congress 2009 - Tuberculosis at different age groups Year: 2009 Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Characteristics of pleural effusions secondary to pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 320s Year: 2001 Pleural effusion in lung cancer and targeted therapy Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 A female with pulmonary artery hypertension and pleural effusion Source: ISSN=ISSN 1810-6838, ISBN=, page=89 Year: 2006 Dasatinib increases endothelial permeability leading to pleural effusion Source: International Congress 2017 – Experimental PH Year: 2017 Dasatinib increases endothelial permeability leading to pleural effusion Source: Eur Respir J, 51 (1) 1701096; 10.1183/13993003.01096-2017 Year: 2018 Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007 Impact of sarcopenia in long-term symptoms in patients with malignant pleural effusion. Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease Year: 2021 Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 63s Year: 2003 A new radiologic appearance of pulmonary thromboembolism: localized pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013